BR112023022224A2 - Urolitina para aumentar função de célula-tronco - Google Patents

Urolitina para aumentar função de célula-tronco

Info

Publication number
BR112023022224A2
BR112023022224A2 BR112023022224A BR112023022224A BR112023022224A2 BR 112023022224 A2 BR112023022224 A2 BR 112023022224A2 BR 112023022224 A BR112023022224 A BR 112023022224A BR 112023022224 A BR112023022224 A BR 112023022224A BR 112023022224 A2 BR112023022224 A2 BR 112023022224A2
Authority
BR
Brazil
Prior art keywords
stem cell
cell function
urolithine
increase stem
increase
Prior art date
Application number
BR112023022224A
Other languages
English (en)
Portuguese (pt)
Inventor
Mukul Girotra
Nicola Vannini
Original Assignee
Ludwig Inst For Cancer Res Ltd
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd, Nestle Sa filed Critical Ludwig Inst For Cancer Res Ltd
Publication of BR112023022224A2 publication Critical patent/BR112023022224A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Primary Cells (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023022224A 2021-05-05 2022-05-02 Urolitina para aumentar função de célula-tronco BR112023022224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21172290 2021-05-05
PCT/EP2022/061666 WO2022233767A1 (en) 2021-05-05 2022-05-02 Urolithin for increasing stem cell function

Publications (1)

Publication Number Publication Date
BR112023022224A2 true BR112023022224A2 (pt) 2024-02-06

Family

ID=75825544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022224A BR112023022224A2 (pt) 2021-05-05 2022-05-02 Urolitina para aumentar função de célula-tronco

Country Status (8)

Country Link
US (1) US20240228966A1 (https=)
EP (1) EP4333832A1 (https=)
JP (1) JP2024516187A (https=)
CN (1) CN117202903A (https=)
AU (1) AU2022270331A1 (https=)
BR (1) BR112023022224A2 (https=)
CA (1) CA3213384A1 (https=)
WO (1) WO2022233767A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
JP7557374B2 (ja) * 2018-04-30 2024-09-27 アマゼンティス エスアー 免疫増強剤としてのウロリチンａ
JP7677893B2 (ja) * 2019-01-18 2025-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法

Also Published As

Publication number Publication date
EP4333832A1 (en) 2024-03-13
CN117202903A (zh) 2023-12-08
US20240228966A1 (en) 2024-07-11
WO2022233767A1 (en) 2022-11-10
AU2022270331A1 (en) 2023-10-12
CA3213384A1 (en) 2022-11-10
JP2024516187A (ja) 2024-04-12
AU2022270331A9 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CL2023001860A1 (es) Composiciones y métodos para reducir hla-a en una célula
BRPI0406389A (pt) Interface de usuário de mensagens integrada com registro baseado em mensagens
BR112015022612A2 (pt) microrganismo recombinante e enzima
BR112015020936A2 (pt) geração de energia integrada e captura de carbono usando células de combustível
BR112022007950A2 (pt) Integração direcionada no locus de alfa-globina em células-tronco e células progenitoras hematopoiéticas humanas
MX2022006882A (es) Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
BR112022012326A2 (pt) Conversor de energia multiportas
ATE539146T1 (de) Säugetier-megakaryozytenstammzelle
AR113150A1 (es) Producción mejorada de etanol libre de glicerol
BR112023022224A2 (pt) Urolitina para aumentar função de célula-tronco
BR112018007971A2 (pt) bateria de hidreto metálico com adição de gás de hidrogênio, gás de oxigênio ou peróxido de hidrogênio
BR112015031679A8 (pt) conjugado de peptídeo-resina, seu uso, processo para sua produção, peptídeo e método para sua preparação
BR112022015953A2 (pt) Variante de mananase, polinucleotídeo que codifica a mananase, construto de expressão, célula hospedeira, métodos para expressar uma variante de mananase e para aumentar a estabilidade de fermentação, preparação enzimática líquida, formulação detergente, e, uso de uma mananase
MX2024008804A (es) Arnbc, uso y metodo de preparacion para el mismo.
BR112023005370A2 (pt) Composições e métodos para aumentar função das células-tronco
BR112023005375A2 (pt) Composições e métodos para aumentar a função de células-tronco
BR112022003515A2 (pt) Tcr de alta afinidade para reconhecer antígeno ssx2
MX2024014930A (es) Sistema de almacenamiento de energia sensible a los parametros de generacion de carbono
BR112023024231A2 (pt) Células t primárias rhd negativas hipoimunogênicas
CL2021003232A1 (es) Sistema de pesaje en movimiento con datos de canal
Simmel Tendencies in German Life and thought since 1870
PL448319A1 (pl) Zastosowanie MMP2, jako regulatora różnicowania ludzkich pluripotencjalnych komórek macierzystych w kierunku komórek β trzustki
TWD240266S (zh) 書寫筆
Rojas et al. Sustainable supplier development practices, firm performance and national culture: a meta-analysis
Schwarz Lexical parallels in calendars and less obvious traces of Chinese influence on ancient Xinjiang languages